• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Introduction to 3-(4-Ethoxybenzyl)piperidine (CAS No. 955315-04-5)

3-(4-Ethoxybenzyl)piperidine, with the CAS number 955315-04-5, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a piperidine ring and a 4-ethoxybenzyl substituent. These structural elements contribute to its potential pharmacological properties and make it a valuable candidate for various applications, particularly in the development of novel therapeutic agents.

The chemical structure of 3-(4-Ethoxybenzyl)piperidine can be represented as C₁₄H₂₁NO₂. The presence of the piperidine ring, a six-membered cyclic amine, imparts basic properties to the molecule, while the 4-ethoxybenzyl group adds aromatic and ether functionalities. These combined features make 3-(4-Ethoxybenzyl)piperidine a versatile compound with potential interactions with various biological targets.

In recent years, significant advancements have been made in understanding the biological activities and potential therapeutic applications of 3-(4-Ethoxybenzyl)piperidine. Research has shown that this compound exhibits promising activity in several areas, including central nervous system (CNS) disorders, pain management, and neurodegenerative diseases. For instance, studies have demonstrated that 3-(4-Ethoxybenzyl)piperidine can modulate neurotransmitter systems, such as serotonin and dopamine, which are crucial for maintaining brain function and mood regulation.

The pharmacological profile of 3-(4-Ethoxybenzyl)piperidine has been extensively studied using both in vitro and in vivo models. In vitro assays have revealed that this compound can selectively bind to specific receptors, such as serotonin receptors (5-HT_2A) and dopamine receptors (D₂). These interactions suggest potential applications in treating conditions like depression, anxiety, and schizophrenia. Furthermore, preclinical studies have shown that 3-(4-Ethoxybenzyl)piperidine can cross the blood-brain barrier efficiently, enhancing its therapeutic potential for CNS disorders.

Beyond its role in CNS disorders, 3-(4-Ethoxybenzyl)piperidine has also shown promise in pain management. Research indicates that this compound can interact with nociceptive pathways and reduce pain sensitivity. This property makes it a potential candidate for developing new analgesic drugs that could offer improved efficacy and reduced side effects compared to existing treatments.

In the context of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, 3-(4-Ethoxybenzyl)piperidine has been investigated for its neuroprotective effects. Studies have shown that this compound can reduce oxidative stress and inflammation in neuronal cells, which are key factors contributing to neurodegeneration. Additionally, it has been found to enhance cognitive function in animal models of these diseases, suggesting its potential as a therapeutic agent for improving cognitive decline.

The synthesis of 3-(4-Ethoxybenzyl)piperidine involves several well-established chemical reactions. One common approach is the nucleophilic substitution of a halide on a benzene ring with an ethoxide ion to form the 4-ethoxybenzyl intermediate. This intermediate is then coupled with a piperidine derivative through a suitable coupling reaction to yield the final product. The synthetic route is highly reproducible and can be scaled up for industrial production.

The safety profile of 3-(4-Ethoxybenzyl)piperidine has been evaluated through extensive toxicological studies. These studies have shown that the compound is generally well-tolerated at therapeutic doses and exhibits low toxicity. However, like any pharmaceutical agent, it is important to conduct thorough clinical trials to ensure its safety and efficacy in human subjects.

In conclusion, 3-(4-Ethoxybenzyl)piperidine (CAS No. 955315-04-5) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and pharmacological properties make it an attractive candidate for developing novel therapeutic agents for CNS disorders, pain management, and neurodegenerative diseases. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic potential, further solidifying its importance in the field.

• 120-20-7(2-(3,4-Dimethoxyphenyl)ethylamine)
• 766487-11-0(3-[(3-methoxyphenyl)methyl]piperidine)
• 893754-76-2(4-(4-ethoxyphenyl)methylpiperidine)
• 37581-26-3(4-(4-methoxyphenyl)methylpiperidine)
• 55-81-2(2-(4-Methoxyphenyl)ethylamine)
• 136422-65-6(3-(4-Methoxybenzyl)piperidine)
• 539-15-1(Hordenine)
• 58-46-8(Tetrabenazine)
• 554-52-9(4-(2-Aminoethyl)-2-methoxyphenol)
• 702-24-9(1-(4-methoxyphenyl)-N-methyl-methanamine)